Implantable cardiac defibrillators for patients with non‐ischaemic cardiomyopathy
References
Additional references
Akl EA, Johnston BC, Alonso‐Coello P, Neumann I, Ebrahim S, Briel M, et al. Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. PLOS One 2013;8(2):e57132. [PUBMED: 23451162]
Al‐Khatib SM, Fonarow GC, Joglar JA, Inoue LY, Mark DB, Lee KL, et al. Primary prevention implantable cardioverter defibrillators in patients with nonischemic cardiomyopathy: a meta‐analysis. JAMA Cardiology 2017;2(6):685‐8. [PUBMED: 28355432]
Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. Journal of the American College of Cardiology 2014;63(12):1123‐33.
Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic‐drug therapy with implantable defibrillators in patients resuscitated from near‐fatal ventricular arrhythmias. New England Journal of Medicine 1997;337(22):1576‐83.
Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401‐6. [PUBMED: 21208779]
Bansch D, Antz M, Boczor S, Volkmer M, Tebbenjohanns J, Seidl K, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 2002;105(12):1453‐8. [PUBMED: 11914254]
Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter‐defibrillator for congestive heart failure. New England Journal of Medicine 2005;352(3):225‐37. [PUBMED: 15659722]
Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac‐resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. New England Journal of Medicine 2004;350(21):2140‐50. [DOI: 10.1056/NEJMoa032423]
Centre for Reviews and Dissemination. Search strategies. www.crd.york.ac.uk/crdweb/searchstrategies.asp#nhseedmedline (accessed 17 July 2017).
Chatterjee S, Biondi‐Zoccai G, Abbate A, D'Ascenzo F, Castagno D, Van Tassell B, et al. Benefits of beta blockers in patients with heart failure and reduced ejection fraction: network meta‐analysis. BMJ (Clinical research ed.) 2013;346:f55. [PUBMED: 23325883]
Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101(11):1297‐302. [PUBMED: 10725290]
Dass S, Holloway CJ, Cochlin LE, Rider OJ, Mahmod M, Robson M, et al. No evidence of myocardial oxygen deprivation in nonischemic heart failure. Circulation. Heart Failure 2015;8(6):1088‐93.
Daughenbaugh LA. Cardiomyopathy: an overview. Journal for Nurse Practitioners 2007;3(4):248‐58.
Derfler MC, Jacob M, Wolf RE, Bleyer F, Hauptman PJ. Mode of death from congestive heart failure: implications for clinical management. American Journal of Geriatric Cardiology 2004;13(6):299‐304.
Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta‐analysis of randomized controlled trials. JAMA 2004;292(23):2874‐9. [PUBMED: 15598919]
Dougherty CM. Psychological reactions and family adjustment in shock versus no shock groups after implantation of internal cardioverter defibrillator. Heart & Lung: the Journal of Critical Care 1995;24(4):281‐91. [PUBMED: 7591795]
Dunbar SB, Warner CD, Purcell JA. Internal cardioverter defibrillator device discharge: experiences of patients and family members. Heart & Lung: the Journal of Critical Care 1993;22(6):494‐501. [PUBMED: 8288452]
Ebrahim S, Akl EA, Mustafa RA, Sun X, Walter SD, Heels‐Ansdell D, et al. Addressing continuous data for participants excluded from trial analysis: a guide for systematic reviewers. Journal of Clinical Epidemiology 2013;66(9):1014‐21.e1. [PUBMED: 23774111]
Ebrahim S, Johnston BC, Akl EA, Mustafa RA, Sun X, Walter SD, et al. Addressing continuous data measured with different instruments for participants excluded from trial analysis: a guide for systematic reviewers. Journal of Clinical Epidemiology 2014;67(5):560‐70. [PUBMED: 24613497]
Golwala H, Bajaj NS, Arora G, Arora P. Implantable cardioverter‐defibrillator for nonischemic cardiomyopathy: an updated meta‐analysis. Circulation 2017;135(2):201‐3. [PUBMED: 27993908]
McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 12 July 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. Journal of the American College of Cardiology 2000;35(5):1245‐55. [PUBMED: 10758967]
Guyatt GH, Nogradi S, Halcrow S, Singer J, Sullivan M, Fallen EL. Development and testing of a new measure of health status for clinical trials in heart failure. Journal of General Internal Medicine 1989;4(2):101‐7.
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383‐94. [PUBMED: 21195583]
Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology 2011;64(4):395‐400. [PUBMED: 21194891]
Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso‐Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence‐‐imprecision. Journal of Clinical Epidemiology 2011;64(12):1283‐93. [PUBMED: 21839614]
Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence‐‐inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294‐302. [PUBMED: 21803546]
Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence‐‐indirectness. Journal of Clinical Epidemiology 2011;64(12):1303‐10. [PUBMED: 21802903]
Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso‐Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence‐‐study limitations (risk of bias). Journal of Clinical Epidemiology 2011;64(4):407‐15. [PUBMED: 21247734]
Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso‐Coello P, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology 2013;66(2):151‐7. [PUBMED: 22542023]
Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables‐binary outcomes. Journal of Clinical Epidemiology 2013;66(2):158‐72. [PUBMED: 22609141]
Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles‐continuous outcomes. Journal of Clinical Epidemiology 2013;66(2):173‐83. [PUBMED: 23116689]
Guyatt GH, Ebrahim S, Alonso‐Coello P, Johnston BC, Mathioudakis AG, Briel M, et al. GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence. Journal of Clinical Epidemiology 2017 May 18 [Epub ahead of print]. [DOI: 10.1016/j.jclinepi.2017.05.005]
Hamner M, Hunt N, Gee J, Garrell R, Monroe R. PTSD and automatic implantable cardioverter defibrillators. Psychosomatics 1999;40(1):82.
Henkel DM, Redfield MM, Weston SA, Gerber Y, Roger VL. Death in heart failure: a community perspective. Circulation. Heart Failure 2008;1(2):91‐7.
Heran BS, Musini VM, Bassett K, Taylor RS, Wright JM. Angiotensin receptor blockers for heart failure. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD003040.pub2; PUBMED: 22513909]
Higgins SL, Hummel JD, Niazi IK, Giudici MC, Worley SJ, Saxon LA, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. Journal of the American College of Cardiology 2003;42(8):1454‐9.
Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration.
Higgins J, Altman G, Sterne J. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. Journal of the American College of Cardiology 1993;22(4 Suppl A):6A‐13A. [PUBMED: 8376698]
Josephson M, Wellens HJJ. Implantable defibrillators and sudden cardiac death. Circulation 2004;109(22):2685‐91.
Kadish A, Quigg R, Schaechter A, Anderson KP, Estes M, Levine J. Defibrillators in nonischemic cardiomyopathy treatment evaluation. Pacing and Clinical Electrophysiology: PACE 2000;23(3):338‐43. [PUBMED: 10750134]
Kober L, Thune JJ, Nielsen JC, Haarbo J, Videbaek L, Korup E, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. New England Journal of Medicine 2016;375(13):1221‐30. [PUBMED: 27571011]
Kuck KH, Cappato R, Siebels J, Rüppel R, CASH Investigators. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest the Cardiac Arrest Study Hamburg (CASH). Circulation 2000;102(7):748‐54.
Ladwig K, Baumert J, Marten‐Mittag B, Kolb C, Zrenner B, Schmitt C. Posttraumatic stress symptoms and predicted mortality in patients with implantable cardioverter‐defibrillators: results from the prospective living with an implanted cardioverter‐defibrillator study. Archives of General Psychiatry 2008;65(11):1324‐30. [DOI: 10.1001/archpsyc.65.11.1324]
Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration.
Luni FK, Singh H, Khan AR, Malik SA, Khawaja O, Riaz H, et al. Mortality effect of ICD in primary prevention of nonischemic cardiomyopathy: a meta‐analysis of randomized controlled trials. Journal of Cardiovascular Electrophysiology 2017;28(5):538‐43. [PUBMED: 28370885]
Marijon E, Leclercq C, Narayanan K, Boveda S, Klug D, Lacaze‐Gadonneix J, et al. Causes‐of‐death analysis of patients with cardiac resynchronization therapy: an analysis of the CeRtiTuDe cohort study. European Heart Journal 2015;36(41):2767‐76.
Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies. Circulation 2006;113(14):1807‐16.
McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Journal of Heart Failure 2012;14(8):803‐69.
McNally EM, Golbus JR, Puckelwartz MJ. Genetic mutations and mechanisms in dilated cardiomyopathy. Journal of Clinical Investigation 2013;123(1):19‐26.
Mirowski M, Reid Philip R, Mower Morton M, Watkins Levi, Gott Vincent L, Schauble James F, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. New England Journal of Medicine 1980;303(6):322‐4.
Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. New England Journal of Medicine 2002;346(12):877‐83. [PUBMED: 11907286]
Mosterd A, Cost B, Hoes AW, De Bruijne MC, Deckers JW, Hofman A, et al. The prognosis of heart failure in the general population. The Rotterdam Study. European Heart Journal 2001;22(15):1318‐27.
O'Leary C, Jones P. The left ventricular dysfunction questionnaire (LVD‐36): reliability, validity, and responsiveness. Heart 2000;83(6):634‐40. [PUBMED: 10814618]
Packer DL, Prutkin JM, Hellkamp AS, Mitchell LB, Bernstein RC, Wood F, et al. Impact of implantable cardioverter‐defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation 2009;120(22):2170‐6. [PUBMED: 19917887]
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Revista Espanola de Cardiologia (English ed.) 2016;69(12):1167. [PUBMED: 27894487]
Pons F, Lupón J, Urrutia A, González B, Crespo E, Díez C, et al. Mortality and cause of death in patients with heart failure: findings at a specialist multidisciplinary heart failure unit. Revista Espanol de Cardiologia 2010;63(3):303‐14.
Poole JE. Present guidelines for device implantation: clinical considerations and clinical challenges from pacing, implantable cardiac defibrillator, and cardiac resynchronization therapy. Circulation 2014;129(3):383‐94. [PUBMED: 24446408]
Rector TS, Kubo SH, Cohn JN. Patients' self‐assessment of their congestive heart failure. Part 2: content, reliability and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire. Heart Failure 1987;3(5):198‐209.
Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rosenqvist M, Beyer T, Block M, den Dulk K, Minten J, Lindemans F. Adverse events with transvenous implantable cardioverter‐defibrillators: a prospective multicenter study. Circulation 1998;98(7):663‐70.
Schron EB, Exner DV, Yao Q, Jenkins LS, Steinberg JS, Cook JR, et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 2002;105(5):589‐94. [PUBMED: 11827924]
Schünemann H, Oxman A, Vist G, Higgins J, Deeks J, Glasziou P, Guyatt G. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from from handbook.cochrane.org.
Sears SF, Conti JB. Quality of life and psychological functioning of ICD patients. Heart 2002;87(5):488‐93.
Shiga T, Hagiwara N, Ogawa H, Takagi A, Nagashima M, Yamauchi T, et al. Sudden cardiac death and left ventricular ejection fraction during long‐term follow‐up after acute myocardial infarction in the primary percutaneous coronary intervention era: results from the HIJAMI‐II registry. Heart (British Cardiac Society) 2009;95(3):216‐20. [PUBMED: 18728065]
Shun‐Shin MJ, Zheng SL, Cole GD, Howard JP, Whinnett ZI, Francis DP. Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta‐analysis of 8567 patients in the 11 trials. European Heart Journal 2017;38(22):1738‐46. [PUBMED: 28329280]
Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL, et al. Amiodarone versus implantable cardioverter‐defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia‐‐AMIOVIRT. Journal of the American College of Cardiology 2003;41(10):1707‐12. [PUBMED: 12767651]
Wiklund I, Lindvall K, Swedberg K, Zupkis RV. Self‐assessment of quality of life in severe heart failure. An instrument for clinical use. Scandinavian Journal of Psychology 1987;28(3):220‐5. [PUBMED: 3441769]
Wolff G, Lin Y, Karathanos A, Brockmeyer M, Wolters S, Nowak B, et al. Implantable cardioverter/defibrillators for primary prevention in dilated cardiomyopathy post‐DANISH: an updated meta‐analysis and systematic review of randomized controlled trials. Clinical Research in Cardiology 2017;106(7):501‐13. [PUBMED: 28213711]
Wu AH, Jaffe AS, Apple FS, Jesse RL, Francis GL, Morrow DA, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B‐type natriuretic peptide or N‐terminal proB‐type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clinical Chemistry 2007;53(12):2086‐96. [PUBMED: 17954494]
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology 2013;62(16):e147‐239. [PUBMED: 23747642]
Yap YG, Duong T, Bland M, Malik M, Torp‐Pedersen C, Køber L, et al. Temporal trends on the risk of arrhythmic vs. non‐arrhythmic deaths in high‐risk patients after myocardial infarction: a combined analysis from multicentre trials. European Society of Cardiology 2005;26(14):1385‐93.
Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 2003;289(20):2685‐94.
Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nature Reviews. Cardiology 2016;13(6):368‐78. [PUBMED: 26935038]
